Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$2 Mln
P/E Ratio
--
P/B Ratio
0.67
Industry P/E
--
Debt to Equity
0.08
ROE
-5.85 %
ROCE
-398.36 %
Div. Yield
0 %
Book Value
3708422
EPS
-7987225
CFO
$-28.65 Mln
EBITDA
$-60.71 Mln
Net Profit
$-62.09 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Ensysce Biosciences Inc (ENSC)
| -57.37 | 0.58 | -58.09 | -57.24 | -90.31 | -84.39 | -- |
|
BSE Sensex
| 2.39 | 4.18 | 4.86 | 8.78 | 11.89 | 20.62 | 11.13 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|
|---|---|---|---|---|---|---|
|
Ensysce Biosciences Inc (ENSC)
| -48.52 | -88.22 | -99.20 | -62.20 | 19.33 | 6.11 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 | 25.27 | 9.57 | 20.86 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 | 14.38 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 36.73 | 9,808.03 | 20.22 | 23.13 | |
| 284.42 | 8,956.09 | 22.08 | 58.42 | |
| 26.83 | 9,559.25 | -- | -28.77 | |
| 103.38 | 10,030.35 | 30.81 | 14.16 |
Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, develops prescription drugs for severe pain relief in opioid misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection (TAAP)... platform, designed to release clinically effective drugs only when exposed to specific physiological conditions; and Multi-Pill Abuse Resistance (MPAR) platform, an over-dose protection opioid prodrug technology. The company's lead product candidate is PF614, a TAAP oxycodone prodrug candidate for the treatment of severe or chronic pain; and PF614-MPAR, a combination product of PF614 and nafamostat for overdose protection. It is also developing PF8001 and PF8026 are extended and immediate-release prodrugs of amphetamine for attention deficit hyperactivity disorder; and PF9001 to treat Opioid use disorder.Ensysce Biosciences, Inc. was founded in 2003 and is based in La Jolla, California. Address: 7946 Ivanhoe Avenue, La Jolla, CA, United States, 92037 Read more
President, CEO & Director
Dr. D. Lynn Kirkpatrick Ph.D.
President, CEO & Director
Dr. D. Lynn Kirkpatrick Ph.D.
Headquarters
La Jolla, CA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Ensysce Biosciences Inc (ENSC) stood at $ 6 Mln as on 31-Dec-24
The share price of Ensysce Biosciences Inc (ENSC) is $3.47 (NASDAQ) as of 23-Apr-2025 14:40 EDT. Ensysce Biosciences Inc (ENSC) has given a return of -90.31% in the last 3 years.
Ensysce Biosciences Inc (ENSC) has a market capitalisation of $ 2 Mln as on 22-Apr-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of Ensysce Biosciences Inc (ENSC) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Ensysce Biosciences Inc (ENSC) and enter the required number of quantities and click on buy to purchase the shares of Ensysce Biosciences Inc (ENSC).
Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, develops prescription drugs for severe pain relief in opioid misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection (TAAP) platform, designed to release clinically effective drugs only when exposed to specific physiological conditions; and Multi-Pill Abuse Resistance (MPAR) platform, an over-dose protection opioid prodrug technology. The company's lead product candidate is PF614, a TAAP oxycodone prodrug candidate for the treatment of severe or chronic pain; and PF614-MPAR, a combination product of PF614 and nafamostat for overdose protection. It is also developing PF8001 and PF8026 are extended and immediate-release prodrugs of amphetamine for attention deficit hyperactivity disorder; and PF9001 to treat Opioid use disorder.Ensysce Biosciences, Inc. was founded in 2003 and is based in La Jolla, California. Address: 7946 Ivanhoe Avenue, La Jolla, CA, United States, 92037
The CEO & director of Dr. D. Lynn Kirkpatrick Ph.D.. is Ensysce Biosciences Inc (ENSC), and CFO & Sr. VP is Dr. D. Lynn Kirkpatrick Ph.D..
There is no promoter pledging in Ensysce Biosciences Inc (ENSC).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,012
|
|
|
990
|
|
|
974
|
|
|
896
|
| Ensysce Biosciences Inc (ENSC) | Ratios |
|---|---|
|
Return on equity(%)
|
-430.76
|
|
Operating margin(%)
|
--
|
|
Net Margin(%)
|
--
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Ensysce Biosciences Inc (ENSC) was $0 Mln.
$1.60
(
